Research

Internet searches can identify drug safety issues well ahead of public alerts

The authors base their findings on an analysis of the anonymised search logs of millions of US web users, who agreed to install a browser add-on and share their online searches with Microsoft throughout 2010. The researchers developed automated tools to analyse the queries of people who searched for information on the antidepressant (paroxetine) and a cholesterol lowering drug (pravastatin), using the search engines Google, Bing and Yahoo.

In 2010, it was not yet public knowledge that taking both these two drugs caused high blood sugar (hyperglycaemia), but the authors later extracted this information by mining the US drugs regulator's medicines side effect reporting system (AERS) and confirming the finding in a separate laboratory study.

In the web log study, the authors looked at whether people who had searched online for either one of the drugs separately, or for both of them, would also search with queries containing terms associated with the symptoms of high blood sugar.

In all, they analysed 82 million drug, symptom, and condition queries from among 6 million web users.

They found that online searches for information on prescription drugs was common, with more than one in 250 people looking up at least one of the 100 top selling drugs in the US, including paroxetine and pravastatin.

For people who searched online for both drugs during the 12 month period, queries were made on the same day in almost a third (29.61%) of searches, while four out of 10 were in the same week. Six out of 10 were made within the same month.

During the study period, those people who looked up both drugs online were almost twice as likely to search for terms associated with high blood sugar as were those who looked up the drugs separately.

One in 10 of those looking up both drugs did this, compared with around one in 20 of those looking up each drug separately. Just 0.3% of all users searched for one or more terms associated with high blood sugar over the 12 months.

These differences in search patterns were evident across the whole period of the study, and were not influenced by public information as the discovery of the interaction between this particular pair of drugs was only made in 2011.

Analysis of other 31 drug pair interactions associated with high blood sugar also indicated similar patterns, suggesting that the value of log analysis is not just confined to paroxetine and pravastatin.

"There is a potential public health benefit in listening to such signals, and integrating them with other sources of information," write the authors. "We see a potentially valuable signal, even though search logs are unstructured, not necessarily related to health, and can include any words entered by users," they add.

And they conclude: "We believe that patient search behaviour directly captures aspects of patients' concerns about sensed [symptoms] and can complement more traditional sources of data for pharmacovigilance [drug safety monitoring]."

Most Popular Now

AstraZeneca licenses Zurampic to Gr…

AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin Ameri...

Read more

Pfizer presents promising data from…

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, nex...

Read more

Bayer Science & Education Found…

Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambit...

Read more

Merck Accelerator expands its reach…

Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Na...

Read more

Call for Abstracts: DIA EuroMeeting…

29 - 31 March 2017, Glasgow, UK. The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and acce...

Read more

AstraZeneca enters commercialisatio…

AstraZeneca today announced it has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anae...

Read more

Boehringer Ingelheim and Harvard sc…

Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of...

Read more

Merck announces survey results expl…

Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks as...

Read more

FDA targets unlawful internet sales…

The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, announced that it took action this week against 4,402 we...

Read more

Promising treatment prospects for i…

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms...

Read more

Digital health: A way for pharma co…

Pharmaceutical companies have an opportunity to use their expertise to play a greater role in healthcare reform, while also revamping their business model. We believe t...

Read more

Merck in agreement with HAPPYneuron…

Merck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, a subsidiary of SBT Group of France, in ...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]